Process method for producing immunomodulatory octapeptide by using brevibacillus laterosporus and application of immunomodulatory octapeptide
By optimizing the fermentation process and carrier of Bacillus lateral sporiosporis, the problems of low yield and high production cost of immunomodulatory octapeptides in animal husbandry are solved, and efficient and stable industrial production of immunomodulatory octapeptides is achieved. The products are suitable for feed additives and other products. Use.
Patent Information
- Application Number
- CN202410715867.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-04
- Publication Date
- 2024-11-08
AI Technical Summary
In animal husbandry, the fermentation of Bacillus brevis lateral spore production of immunomodulatory octapeptides has problems such as low yield, small scale and high production costs, making it difficult to achieve industrial production.
Provide a Brevibacillus lateosporus that efficiently and stably expresses immunomodulatory octapeptides. The fermentation medium is optimized using an optimized fermentation process including strain activation, seed shake flask culture, fermentation tank culture, concentration and spray drying. Formulation and conditions, a composite carrier of corn starch and light calcium carbonate is combined to improve yield and stability.
It has achieved high yield of immunomodulatory octapeptides, with a product content of up to 72.65 mg/g. It is suitable for industrial production and reduces production costs. It has good product stability and is suitable for a variety of purposes.
Smart Images

Figure CN118909821A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microorganisms, and specifically relates to Brevibacillus laterosporus and a process method for producing an immunomodulatory octapeptide using the same. Background Art
[0002] With the development of society and the improvement of people's living standards, more and more people are concerned about the safety and health of food. In animal husbandry, feed additives are an important component of feed, and their quality directly affects the quality of feed, which in turn affects the quality of livestock and poultry products. Low doses of antibiotics were once widely added to feed to improve the immunity and growth indicators of animals, but the abuse of antibiotics has led to increased bacterial resistance.
[0003] Antimicrobial peptides are secondary metabolites produced by microorganisms (such as some Bacillus), and are a class of peptide molecules with strong bactericidal ability. They also have biological activities such as immunomodulation, free radical scavenging and protease inhibition. Some antimicrobial peptides are also called immunomodulatory peptides, which have activities such as immunomodulation, promoting chemotaxis of immune cells, and prolonging the life of neutrophils. They can participate in regulating innate and adaptive immune responses and are important mediators for the body to defend against the invasion of foreign substances. Adding immunomodulatory peptides to livestock and poultry feed can improve the immunity of livestock and poultry and their ability to resist viral and bacterial infections. It is a safe, green and pollution-free feed additive that can replace traditional antibiotics.
[0004] The immunomodulatory octapeptide is a non-ribosomal peptide secondary metabolite of the octapeptin family expressed by Brevibacillus laterosporus. It has a strong bactericidal effect on both Gram-positive and Gram-negative pathogens, and its bactericidal ability against Escherichia coli and Pseudomonas aeruginosa is significantly stronger than that against Staphylococcus aureus. The MIC / MBC of the immunomodulatory octapeptide against Gram-negative bacteria is comparable to that of polymyxin B, which is currently used clinically, indicating that the immunomodulatory octapeptide has certain application potential in animal husbandry.
[0005] At present, there are many problems in the industrial production process of immunomodulatory octapeptide products obtained by fermentation with Brevibacillus laterosporus, such as low fermentation production yield, small scale, high production cost, etc., which makes it difficult to move from laboratory to large-scale industrial production. Therefore, optimizing the fermentation production process for large-scale industrial production of immunomodulatory octapeptide is a key issue that needs to be solved urgently. Summary of the invention
[0006] In view of the above problems, the present invention aims to provide a Brevibacillus laterosporus ( Brevibacillus laterosporus ), can be used to produce immunomodulatory peptide products that meet industrial requirements.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is as follows: The present invention provides a Brevibacillus laterosporus ( Brevibacillus laterosporus ), which is deposited in China Center for Type Culture Collection with a deposit number of CCTCC NO: M2024715, and can efficiently and stably express the immunomodulatory octapeptide. The present invention also provides the use of the Brevibacillus laterosporus in the fermentation production of the immunomodulatory octapeptide.
[0008] An immunomodulatory peptide product, comprising the above-mentioned Brevibacillus laterosporus fermentation product. Preferably, the product also includes a composite carrier, the carrier comprising two or more of corn starch, light calcium carbonate and gain powder; more preferably, the composite carrier comprises corn starch, light calcium carbonate, etc. uniformly mixed in a mass ratio of 1: (0.2~2). The carrier and the fermentation concentrate of the present invention form a homogeneous powder in a spray drying tower, further improving the stability of the immunomodulatory octapeptide.
[0009] The present invention further provides a process for producing an immunomodulatory octapeptide product by fermentation, comprising fermentation with the Brevibacillus laterosporus, separation and concentration of the fermentation liquid, and drying.
[0010] The above fermentation comprises the following steps: 1) Activation of bacterial strains: inoculate Brevibacillus laterosporus with the deposit number of CCTCC NO: M2024715 into NB solid medium for culture and activation; 2) Seed shake flask culture: The activated single bacterial colony in step 1) is inoculated into a sterilized soy peptone medium shake flask to obtain seed solution; 3) Fermentation tank culture: The seed solution obtained in step 2) is inoculated into a fermentation medium for fermentation culture to obtain an immunomodulatory octapeptide fermentation bacterial solution.
[0011] Preferably, the seed shake flask culture conditions in step 2) are: 32-38°C, 200 rpm, shake flask culture for 12-18 h, until the bacterial cell concentration reaches 10 7 ~10 8 cfu / mL. Preferably, the formula of the fermentation medium in step 3) is: sucrose dosage 20 g / L, corn syrup dosage 30 g / L, magnesium sulfate dosage 0.5 g / L. Preferably, the conditions of the fermentation tank culture in step 3) are: ventilation volume 1.0 vvm, stirring speed 120 rpm, dissolved oxygen 20-30%, fermentation temperature 33 °C, process pH 6.8, and fermentation culture time 34 h.
[0012] The production method further comprises: after placing the fermented bacterial liquid in a tank, adjusting the pH value to 2-3, and then adding cyclodextrin.
[0013] The fermentation liquid separation and concentration are centrifugal separation, ceramic filtration and nanofiltration membrane concentration to obtain the fermentation concentrate.
[0014] The above drying is carried out in a spray drying tower. Preferably, the inlet temperature in the spray drying tower is 150-180°C, the outlet temperature is 70-90°C, and the drying time is 9-20 hours. The spray drying is carried out on a composite carrier. After spray drying, an immunomodulatory octapeptide product is finally obtained. Beneficial Effects
[0015] The present invention screened a strain of Brevibacillus laterosporus that produces a high yield of immunomodulatory octapeptide ( Brevibacillus laterosporus ), broadening the production strains of immunomodulatory octapeptides.
[0016] The immunomodulatory octapeptide product is produced by fermentation with Brevibacillus laterosporus of the present invention, and the immunomodulatory octapeptide content can reach up to 72.65 mg / g. The product is light yellow powder with soft and moist color, uniform texture, and fermentation aroma. It is suitable for industrial production and can be used for various purposes such as feed additives.
[0017] The invention optimizes the nitrogen source, carbon source and trace element dosage in the immunoregulatory octapeptide fermentation medium, optimizes the ventilation volume, stirring speed, dissolved oxygen, process pH, fermentation temperature and fermentation time in the fermentation process, and obtains the best balance between production cost and product yield.
[0018] 4. The post-treatment process of the present invention solves the problem that the fermentation product of the immunomodulatory octapeptide is difficult to separate from the culture medium after fermentation. Sterilization and concentration are performed only through centrifugation and ceramic membrane filtration-nanofiltration membrane concentration system, thereby reducing product losses.
[0019] 5. The process of the present invention is simple, easy to operate, has a short fermentation cycle, and has a low post-processing production cost, and can be applied to large-scale production applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Comparison of PCR amplification results in the identification of Brevibacillus laterosporus strains; Figure 2 Sample image of immunomodulatory octapeptide product; Figure 3 The standard curve diagram of the immunomodulatory octapeptide detection in Example 1; Figure 4 Chromatogram of the immunomodulatory octapeptide sample detection in Example 1; Figure 5 The result diagram of the content of the immunomodulatory octapeptide product in Example 1; Figure 6 The result diagram of the content of the immunomodulatory octapeptide in Example 2; Figure 7 The result diagram of the content of the immunomodulatory octapeptide in Example 3; Figure 8 The result diagram of the content of the immunomodulatory octapeptide in Example 4; Fig. 9 The result diagram of the content of the immunomodulatory octapeptide in Example 5; Fig.10 The result diagram of the content of the immunomodulatory octapeptide obtained in Example 6; Fig.11 The result diagram of the content of the immunomodulatory octapeptide obtained in Example 7; Fig.12 The result diagram of the content of the immunomodulatory octapeptide obtained in Example 8; Fig.13 The result diagram of the content of the immunomodulatory octapeptide obtained in Example 9; Fig.14 A graph showing the results of the acid-base stability test of the immunomodulatory octapeptide in Example 10; Fig.15 Graph showing the results of the temperature stability test of the immunomodulatory octapeptide in Example 11. DETAILED DESCRIPTION
[0021] The present invention is described below through specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods well known to those skilled in the art. In addition, the specific embodiments of the present invention should be understood as illustrative rather than limiting the scope of protection of the present invention, and the operating essence and scope of protection of the present invention are defined by the claims. For those skilled in the art, various changes and modifications to the materials, addition amounts, and fermentation conditions in the embodiments of the present invention, without violating the essence and scope of the present invention, all belong to the scope of protection of the present invention.
[0022] The strain used in the present invention is Brevibacillus laterosporus M811 isolated from the soil of Hewanzi Village, Yongchuan District, Chongqing City (N 29°19′54″, E 105°41′11″). The strain was deposited in the China Center for Type Culture Collection on April 25, 2024, address: Wuhan University, Wuhan, China, and classified and named Brevibacillus laterosporus M811, with a preservation number of CCTCC NO: M2024715.
[0023] The strain isolated by the present invention has been identified and its morphological characteristics are: the colony is transparent beige with a shiny surface; the bacteria are slender rod-shaped, about 2.0×1.0 μm in size, with flagella around the bacteria, can form oval spores, and are Gram-positive. The 16S rRNA gene of the strain was amplified by PCR, sequenced, and phylogenetic analysis was performed. Figure 1As shown. It was identified as Brevibacillus laterosporus and named Brevibacillus laterosporus ( Brevibacillus Laterosporus )M811.
[0024] The NB culture medium used in the present invention is composed of: 10 g / L tryptone, 5 g / L yeast extract, and 10 g / L sodium chloride, which are purchased from Beijing Solebow Technology Co., Ltd. The soy peptone culture medium used in the present invention is purchased from Beijing Solebow Technology Co., Ltd. The corn steep liquor powder, sucrose, and magnesium sulfate culture medium components are all commercially available culture medium components.
[0025] Example 1
[0026] A fermentation production process for an immunomodulatory octapeptide comprises the following steps: 1) Slant strain activation: The Brevibacillus laterosporus M811 refrigerated tube strain with the deposit number of CCTCC NO: M2024715 was inoculated into NB slant medium and cultured for 16 h; 2) Seed shake flask culture: The single colony cultured on the slant was inoculated into a medium shake flask and cultured in LB medium at 38°C and 200 rpm for 16 h until the cell concentration reached 10 7 ~10 8 cfu / mL, and the seed solution of Brevibacillus laterosporus was obtained; 3) Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at a 5% inoculation rate for fermentation culture. The fermentation medium formula was as follows: sucrose dosage 5, 10, 20, 30 g / L, corn syrup dosage 10 g / L, magnesium sulfate dosage 0.3 g / L. Process control conditions: ventilation volume 0.5 vvm, stirring speed 100 rpm, dissolved oxygen 0-10%, fermentation temperature 32 °C, process pH 6.5, fermentation culture time 30 h. Obtain immune modulating octapeptide fermentation broth; 4) After the fermentation liquid is placed in a tank, the pH value is adjusted to 2-3, and then cyclodextrin is added in an amount of 10-20 g / L. Centrifugation is performed at 3700 rpm for 30 min, and Dow filter membrane (feed / discharge pressure difference 2.4 Mpa) is used for 30 min-nanofiltration concentration (feed / discharge pressure difference 0.8 Mpa) is performed for 45 min. Then, it is mixed with a composite carrier (corn starch and light calcium carbonate are uniformly mixed in a mass ratio of 1: (0.2-2)) in a spray drying tower and spray-dried. The ratio of carrier / fermentation concentrate is 20-40 g / L. During the spray drying process, the inlet temperature in the spray drying tower is 160 °C, the outlet temperature is 80 °C, and the drying time is 13 h. The immunomodulatory octapeptide product is obtained, such as Figure 2 As shown; 5) Detection of immunomodulatory octapeptide content Prepare a certain concentration of immunomodulatory octapeptide reference substance (chromatographically pure 97.89%) working stock solution, dilute the working stock solution in a two-fold gradient, and obtain a series of multiple concentrations of reference substance solutions. After the HPLC meets the system adaptability requirements, load 10 uL of each gradient of immunomodulatory octapeptide reference substance solution and obtain the detection spectrum of the sample at an absorption wavelength of 220 nm. Repeat the detection of each concentration of the reference substance solution 3 times to obtain the detection peak area of the sample. Calculate the average peak area and make a standard curve based on the corresponding loading solution concentration, that is, Figure 3 The standard curve is shown.
[0027] Weigh 1 g of the immunomodulatory octapeptide product obtained in step 4) and place it in a 25 mL volumetric flask. Add an appropriate amount of ultrapure water and treat it with ultrasound for 10-15 min before diluting it to 25 mL. Transfer the resulting solution to a centrifuge tube and centrifuge it at 8000 rpm and 4 °C for 10 min. The supernatant obtained was filtered through a 0.22 μm filter membrane and then tested with a high performance liquid chromatograph. The obtained liquid chromatogram is shown in the figure below. Figure 4 As shown, each sample was tested twice to obtain the chromatographic peak area of the immunomodulatory octapeptide.
[0028] The content of alicyclic peptide in the immunomodulatory octapeptide product of the present invention was calculated based on the retention time of the standard and the corresponding retention time and peak area of the product sample of the present invention. The results are as follows: Figure 5 shown.
[0029] The calculation formula is as follows:
[0030] Example 2
[0031] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 10, 20, 30, 50 g / L corn syrup powder, and 0.3 g / L magnesium sulfate. Process control conditions: ventilation volume 0.5 vvm, stirring speed 100 rpm, dissolved oxygen 0-10%, fermentation temperature 32 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0032] Example 3
[0033] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.3, 0.5, 0.7, and 1 g / L magnesium sulfate. Process control conditions: ventilation volume 0.5 vvm, stirring speed 100 rpm, dissolved oxygen 0-10%, fermentation temperature 32 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0034] Example 4
[0035] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 0.5, 0.8, 1.0, 1.2 vvm, stirring speed 100 rpm, dissolved oxygen 0-10%, fermentation temperature 32 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0036] Example 5
[0037] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 1.0 vvm, stirring speed 100, 120, 140, 160 rpm, dissolved oxygen 0-10%, fermentation temperature 32 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0038] Example 6
[0039] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 1.0 vvm, stirring speed 120 rpm, dissolved oxygen 0-10, 10-20, 20-30, 30-40%, fermentation temperature 32 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0040] Example 7
[0041] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 1.0 vvm, stirring speed 120 rpm, dissolved oxygen 20-30%, fermentation temperature 32, 33, 34, 35 °C, process pH 6.5, and fermentation culture time 30 h. The immunomodulatory octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0042] Example 8
[0043] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 1.0 vvm, stirring speed 120 rpm, dissolved oxygen 20-30%, fermentation temperature 33 °C, process pH 6.5, 6.8, 7.2, 7.5, and fermentation culture time 30 h. The immune-regulating octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0044] Example 9
[0045] Fermentation tank culture: The obtained seed liquid was inoculated into the fermentation medium at an inoculum rate of 5% for fermentation culture. The fermentation medium formula was as follows: 20 g / L sucrose, 30 g / L corn syrup powder, and 0.5 g / L magnesium sulfate. Process control conditions: ventilation volume 1.0 vvm, stirring speed 120 rpm, dissolved oxygen 20-30%, fermentation temperature 33 °C, process pH 6.8, fermentation culture time 30, 32, 34, 36, 38, 40 h. The immune-regulating octapeptide fermentation broth was obtained, and other fermentation and post-treatment processes were the same as in Example 1.
[0046] Example 10
[0047] The immunomodulatory octapeptide product was prepared into a solution with a concentration of 500 μg / mL using ultrapure water, and the pH was adjusted to 2.0, 4.0, 6.0, 7.0, 8.0, 10.0 and 12.0 using hydrochloric acid and sodium hydroxide solutions, respectively. Samples were taken at 0, 0.5, 1, 2, 3, 4, 5 and 6 h for high performance liquid chromatography detection. The degradation retention rate obtained by liquid chromatography detection was used to evaluate the stability of the immunomodulatory octapeptide in aqueous solutions of different pH values. The results are shown in Figure 2. Fig.14 shown.
[0048] Embodiment 11
[0049] The immunomodulatory octapeptide product was prepared into a solution with a concentration of 500 μg / mL using ultrapure water and placed in an environment of 37, 45, 65, 85, and 100 °C. Samples were taken at 0, 0.5, 1, 2, 3, 4, 5, and 6 h for HPLC detection. The degradation retention rate obtained by HPLC detection was used to evaluate the stability of the immunomodulatory octapeptide in different temperature environments. The results are shown in Figure 2. Fig.15 shown.
[0050] The test results of product content of Examples 1 to 9 of the present invention are shown in Figures 5 to 12 .
[0051] from Figure 2 It can be seen that in Example 1, the fermentation liquid obtained by fermenting Brevibacillus laterosporus M811 was centrifuged, filtered through a ceramic membrane, and concentrated by nanofiltration, and then mixed with a composite carrier in a spray drying tower and spray-dried to obtain a light yellow powder with uniform color and a fermented aroma. Figure 4 As shown in the figure, the content of immunomodulatory octapeptide in the product increases first and then decreases with the increase of sucrose dosage in the culture medium. When the sucrose dosage is 20 g / L, the content of immunomodulatory octapeptide in the product reaches the highest value of 38.26 mg / g.
[0052] In Example 2, the amount of sucrose in the culture medium was fixed at 20 g / L, and corn syrup powder was used as a nitrogen source to optimize its amount in the culture medium. The results are as follows: Figure 5 As shown in the figure, the content of immunomodulatory octapeptide in the product first increased and then decreased with the increase of corn syrup dosage in the culture medium. When the corn syrup dosage was 30 g / L, the content of immunomodulatory octapeptide in the product reached the highest value of 41.59 mg / g.
[0053] In Example 3, the amount of sucrose in the culture medium was fixed at 20 g / L, the amount of corn syrup powder was 30 g / L, and magnesium sulfate was used as a trace element to optimize its amount in the culture medium. The results are as follows: Figure 6 As shown. The content of immunomodulatory octapeptide in the product showed a trend of first increasing and then decreasing with the increase of magnesium sulfate dosage. When the dosage of magnesium sulfate was 0.5 g / L, the content of immunomodulatory octapeptide in the product reached the highest value of 54.33 mg / g. This shows that the increase in the amount of carbon, nitrogen source and inorganic salt (sucrose, corn syrup powder, magnesium sulfate) in the fermentation medium is conducive to the production of immunomodulatory octapeptide by the strain. However, after exceeding a certain threshold, the yield of immunomodulatory octapeptide does not increase with the increase of carbon, nitrogen source and inorganic salt dosage. After optimization, the optimal fermentation medium formula of immunomodulatory octapeptide is: sucrose 20 g / L, corn syrup powder 30 g / L, magnesium sulfate 0.5 g / L.
[0054] In addition, based on the optimization of the culture medium, the fermentation conditions were optimized. In Example 4, the fermentation results of different ventilation rates are shown in FIG. Figure 7 When the ventilation volume was 1 vvm, the content of immunomodulatory octapeptide in the product was 52.21 mg / g, and further increase in ventilation volume did not significantly increase the yield of immunomodulatory octapeptide.
[0055] Based on Examples 1 to 4, the fermentation stirring speed was optimized in Example 5. The results are as follows Figure 8 As shown in Figure 2. When the stirring speed is 120 rpm, the content of immunomodulatory octapeptide in the product reaches the maximum value, which is 56.07 mg / g. When the stirring speed is further increased, the content of immunomodulatory octapeptide shows a downward trend.
[0056] Based on Examples 1 to 5, Example 6 optimized the concentration of dissolved oxygen in the fermentation medium. The results are as follows: Fig. 9 As shown in Figure 2. When the dissolved oxygen concentration is 10-20%, the content of immunomodulatory octapeptide in the product reaches the maximum value, which is 57.84 mg / g. When the dissolved oxygen concentration increases further, the content of immunomodulatory octapeptide shows a downward trend.
[0057] Based on Examples 1 to 6, the fermentation temperature was optimized in Example 7. The results are as follows Fig.10 When the fermentation temperature was 33 °C, the content of immunomodulatory octapeptide in the product reached the maximum value of 58.98 mg / g. When the temperature was further increased, the content of immunomodulatory octapeptide showed a downward trend.
[0058] Based on Examples 1 to 7, the pH of the fermentation process was optimized in Example 8. The results are as follows Fig.11 As shown in Figure 2, when the pH value of the fermentation process was 6.8, the content of the immunomodulatory octapeptide in the product reached a maximum value of 65.09 mg / g. When the pH value of the fermentation process increased further, the content of the immunomodulatory octapeptide showed a downward trend.
[0059] Based on Examples 1 to 8, the fermentation time was optimized in Example 9, and the results were as follows Fig.12 As shown in the figure. When the fermentation time was 34 h, the content of immunomodulatory octapeptide in the product reached the maximum value of 72.65 mg / g. As the fermentation time was further extended, the content of immunomodulatory octapeptide showed a downward trend.
[0060] In order to balance the fermentation cost and the optimal result of the immunomodulatory octapeptide product content, the fermentation process was set to: aeration 1 vvm, stirring speed 120 rpm, dissolved oxygen 10-20%, temperature 33 °C, fermentation process pH 6.8, and fermentation time between 34 and 36 h. After stopping the fermentation, the immunomodulatory octapeptide product was obtained by centrifugation, ceramic membrane filtration, nanofiltration concentration, and finally spray drying. This embodiment can balance the fermentation cost and the yield of the immunomodulatory octapeptide product to the greatest extent.
[0061] Further acid-base stability test results, such as Fig.14 As shown in the figure, the degradation residual rate of the immunomodulatory octapeptide is maintained at more than 97% under the set acid-base conditions and incubation time, indicating that the immunomodulatory octapeptide can stably exist under acidic or alkaline conditions.
[0062] The thermal stability test results of the immunomodulatory octapeptide, such as Fig.15 As shown in the figure, after incubation at 100 °C for 3-6 h, the degradation residual rate of the immunomodulatory octapeptide decreased to 90-90.54%, while it could stably exist under other set temperature and time conditions, and the degradation residual rate was maintained above 95%, showing excellent thermal stability.
[0063] The above examples demonstrate that: High yield: The content of immunomodulatory octapeptide in the product can reach 38~72.65mg / g.
[0064] The balance between production cost and product output: 1 kg The product costs about 120 NTD .
[0065] 3. The product is in the form of homogeneous powder. The immunomodulatory octapeptide has good stability and can exist stably in a pH 2-10 aqueous solution and a high temperature environment of 100°C.
Claims
1. A Brevibacillus laterosporus, which is deposited in China Center for Type Culture Collection with a deposit number of CCTCC NO: M2024715.
2. Use of Brevibacillus laterosporus as claimed in claim 1 in the production of immunomodulatory octapeptide products.
3. An immunomodulatory peptide product comprising the fermentation product of Brevibacillus laterosporus according to claim 1.
4. The immunomodulatory peptide product as claimed in claim 3, comprising a composite carrier, wherein the carrier comprises two or more of corn starch, light calcium carbonate and gain powder.
5. The immunomodulatory peptide product as described in claim 4, wherein the composite carrier comprises corn starch, light calcium carbonate, etc., which are uniformly mixed in a mass ratio of 1:0.2~2.
6. A process for producing an immunomodulatory octapeptide product by fermentation, comprising fermentation with Brevibacillus laterosporus as claimed in claim 1, separation, concentration and drying of the fermentation liquid.
7. The process for producing immunomodulatory octapeptide by fermentation as claimed in claim 6, wherein the fermentation comprises the following steps: 1) Activation of bacterial strains: inoculating the Brevibacillus laterosporus described in claim 1 into NB solid culture medium for culture and activation; 2) Seed shake flask culture: The activated single bacterial colony in step 1) is inoculated into a sterilized soy peptone medium shake flask to obtain seed solution; 3) Fermentation tank culture: The seed solution obtained in step 2) is inoculated into a fermentation medium for fermentation culture to obtain an immunomodulatory octapeptide fermentation bacterial solution.
8. The process for producing an immunomodulatory octapeptide product by fermentation as claimed in claim 7, wherein the seed shake flask culture conditions in step 2) are: 32-38°C, 200 rpm, shake flask culture for 12-18 h, until the bacterial cell concentration reaches 10 7 ~10 8 cfu / mL; preferably, the formula of the fermentation medium in step 3) is: sucrose dosage 20 g / L, corn syrup dosage 30 g / L, magnesium sulfate dosage 0.5 g / L; preferably, the fermentation tank culture conditions in step 3) are: ventilation volume 1.0vvm, stirring speed 120rpm, dissolved oxygen 20-30%, fermentation temperature 33°C, process pH 6.8, and fermentation culture time 34h.
9. The process for producing an immunomodulatory octapeptide product by fermentation as claimed in claim 6, 7 or 8, further comprising: After placing the fermented bacterial liquid in the tank, adjust the pH value to 2-3 and then add cyclodextrin.
10. The process for producing an immunomodulatory octapeptide product by fermentation according to claim 6, 7, 8 or 9, wherein the drying is performed in a spray drying tower. Preferably, the inlet temperature in the spray drying tower is 150-180°C, the outlet temperature is 70-90°C, and the drying time is 9-20 h; and the spray drying is performed on a composite carrier.
Citation Information
Patent Citations
Brevibacillus laterosporus, antibacteriallipopeptide and application thereof to agriculture and food
CN110577910A
Low-toxicity high-stability antibacterial peptide synthesized based on cyclic lipopeptide Brevicidine and application of low-toxicity high-stability antibacterial peptide
CN117024514A
Magnetic montmorillonite material as well as preparation method and application thereof
CN118320781A
Octapeptide, preparation method and application of octapeptide in antibiosis or immunoregulation
CN119119206A
Composition for promoting plant growth and use thereof
CN119234828A
Cited By
Geobacillus thermodenitrificans and method for producing alicyclic peptide by fermenting geobacillus thermodenitrificans
CN117343855A
Octapeptide, preparation method and application of octapeptide in antibiosis or immunoregulation
CN119119206A
An octapeptide, a preparation method thereof and applications thereof in antibacterial or immunomodulation
CN119119206B
